CEPI awards up to US$23.4 million to Valneva for late-stage development of a single-dose Chikungunya vaccine

NEXT STORY
Curetis to Present at Solebury Trout European Biotech Investor Day in NYC
PREV STORY
Roxadustat China Phase 3 Trial for Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine (NEJM)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aptose Biosciences and CrystalGenomics Announce Issuance of Japanese Patent for CG-806

SAN DIEGO, TORONTO, and SEOUL, July 10, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ...

author_avatar
NASDAQ Market News

Binford Pet Wellness Clinic Encourages Philosophy of Pet Wellness

INDIANAPOLIS, Aug. 16, 2015 (GLOBE NEWSWIRE) -- Binford Pet Wellness Clinic of Indianapolis, Indiana, ...

author_avatar
NASDAQ Market News

Enzymatica AB: Top-line results of new clinical trial

Enzymatica today announced the results from the clinical study ENZY-002, a trial investigating the ...

author_avatar
NASDAQ Market News